Supplementary Figure 10. Alterations of myeloid populations in an orthotopic KP lung tumor model with short-term treatment. A–G, Flow cytometry analysis of myeloid populations of CD11b$^+$ (**A**), CD11b$^+$Ly6G$^+$ (TAN) (**B**), CD11b$^+$Gr1$^+$ (MDSC) (**C**), CD11b$^+$Ly6G$^-$SiglecF$^+$ (eosinophil) (**D**), CD11c$^+$ (**E**), CD11c$^+$CD103$^+$ (CD103$^+$ DC) (**F**) and CD11c$^+$CD103$^-$ (Alveolar macrophage) (**G**) in CD45$^+$ cells. **H, I,** Flow cytometry analysis of CD80$^+$ (**H**) and CD86$^+$ (**I**) populations in macrophages. For all flow cytometry analyses, whole tumor-bearing lungs from the IV injection model were harvested and processed after 1 week of treatment. (Ctrl, n=5; PD-1 ab, n=5; Asf1a KO, n=5; Asf1a KO + PD-1 ab, n=5). * p <0.05 (ns, not significant)